Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Accurate DCE-MRI Measurement of Glioblastoma using Point-of-care Portable Perfusion Phantom

Award Number: R03CA245986
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2021
PERIOD OF PERFORMANCE END DATE: 03/31/2024

Group Awards By:

View Award Description

Accurate DCE-MRI Measurement of Glioblastoma using Point-of-care Portable Perfusion Phantom - PROJECT SUMMARY / ABSTRACT The goal of this R03 study is to conduct a pilot study testing whether the variability in quantitative DCE- MRI measurement of glioblastoma across different scanners will be significantly reduced when the UAB-invented perfusion phantom, P4 (Point-of-care Portable Perfusion Phantom), is used for error correction, leading to better differentiation between pseudo-progression and true-progression. This is an essential step before validating the utility of P4 in an extended multi-site clinical trial. Pseudo-progression is known to be associated with better clinical outcomes, thus pseudo-progression mistaken for true-progression may result in discontinuation of an effective therapy. Pseudo-progression is a local inflammatory reaction caused by irradiation and enhanced by concurrent chemotherapy, which leads to transient increase of blood brain barrier (BBB) permeability. The BBB, however, is also disrupted by neoplasm, thus both pseudo- and true-progressions appear with increased contrast enhancement in MRI, and there are no established techniques to differentiate between them. The contrast- enhancing lesions of pseudo-progression are due to inflammatory BBB disruption, whereas those of true- progression are caused by neoplastic BBB disruption. Thus, true-progression typically presents higher perfusion than pseudo-progression does. DCE-MRI has the potential to differentiate between pseudo- and true- progressions of glioblastoma, as it can assess the blood perfusion with minimal susceptibility artifacts, but the measurement variability remains a major concern. The P4 is small enough to be imaged concurrently in the bore of a standard MRI scanner with a patient, serving as an internal reference to measure and compensate the scanner-dependent variation in quantitating perfusion parameters. The P4 successfully reduces the variability in DCE-MRI measurement of various human tissues in our previous studies. We now hypothesize that the variability in quantitative DCE-MRI measurement of glioblastoma across different scanners will also be significantly reduced when MRI system-driven error is corrected using the P4. In this study, a total of 12 patients with a newly (or enlarged) enhancing glioblastoma after adjuvant chemoradiation therapy will be recruited. Each patient will be imaged with two different 3T MRI scanners within a 3-day period, and the two DCE-MRI measurements will be compared to determine the data reproducibility before and after P4-based error correction and to validate the utility of the P4 for accurate quantitative DCE-MRI measurement of glioblastoma. Also it will be examined whether the differentiation between pseudo- and true-progressions of glioblastoma can be improved in quantitative DCE-MRI measurement when the P4 is used for error correction.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Detection and Diagnosis Research	000	2	7/16/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $74,250 )
2022	2022	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Detection and Diagnosis Research	000	2	3/9/2022	NON-COMPETING CONTINUATION	$74,250
														Subtotal = $74,250

Issue Date FY: 2021 ( Subtotal = $74,250 )
2021	2021	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Detection and Diagnosis Research	000	1	3/24/2021	NEW	$74,250
														Subtotal = $74,250

Grand Total All Awards = $148,500

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Accurate DCE-MRI Measurement of Glioblastoma using Point-of-care Portable Perfusion Phantom

Award Number: R03CA245986

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2021

PERIOD OF PERFORMANCE END DATE: 03/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer